Prophylaxis of human toxoplasmosis: a systematic review

References

• Shwab EK, Zhu XQ, Majumdar D, et al. Geographical patterns of Toxoplasma gondii genetic diversity revealed by multilocus PCR-RFLP genotyping. Parasitology. 2014;141(04):453–461. 10.1017/S0031182013001844
   PubMed Web of Science ®Google Scholar
• SYROCOT (Systematic Review on Congenital Toxoplasmosis) study group, Thiebaut R, Leproust S, et al. Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients’ data. Lancet. 2007;369(9556):115–122.
   PubMed Web of Science ®Google Scholar
• Baril L, Ancelle T, Goulet V, et al. Risk factors for Toxoplasma infection in pregnancy: a case-control study in France. Scand J Infect Dis. 1999;31(3):305–309.
   PubMedGoogle Scholar
• Cook AJ, Gilbert RE, Buffolano W, et al. Sources of toxoplasma infection in pregnant women: European multicentre case-control study. European research network on congenital toxoplasmosis. BMJ. 2000;321(7254):142–147. 10.1136/bmj.321.7254.142
   PubMed Web of Science ®Google Scholar
• Kapperud G, Jenum PA, Stray-Pedersen B, et al. Risk factors for toxoplasma gondii infection in pregnancy: results of a prospective case-control study in Norway. Am J Epidemiol. 1996;144(4):405–412. 10.1093/oxfordjournals.aje.a008942
   PubMed Web of Science ®Google Scholar
• Bobic B, Nikolic A, Djurkovic-Djakovic O. Identification of risk factors for infection with Toxoplasma gondii in Serbia as a basis of a program for prevention of congenital toxoplasmosis. Srp Arh Celok Lek. 2003;131(3–4):162–167. 10.2298/SARH0304162B
   PubMedGoogle Scholar
• Foulon W, Naessens A, Lauwers S, et al. Impact of primary prevention on the incidence of toxoplasmosis during pregnancy. Obstet Gynecol. 1988;72(3 Pt 1):363–366.
   PubMed Web of Science ®Google Scholar
• Paquet C, Yudin MH. Toxoplasmosis in pregnancy: prevention, screening, and treatment. J Obstet Gynaecol Can. 2013;35(1):78–79. 10.1016/S1701-2163(15)31053-7
   PubMedGoogle Scholar
• Cortina-Borja M, Tan HK, Wallon M, et al. Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis: an observational prospective cohort study. PLoS Med. 2010;7(10):e1000351.
   PubMed Web of Science ®Google Scholar
• Avelino MM, Amaral WN, Rodrigues IM, et al. Congenital toxoplasmosis and prenatal care state programs. BMC Infect Dis. 2014;14:41. 10.1186/1471-2334-14-33
   PubMed Web of Science ®Google Scholar
• Rodrigues IM, Costa TL, Avelar JB, et al. Assessment of laboratory methods used in the diagnosis of congenital toxoplasmosis after maternal treatment with spiramycin in pregnancy. BMC Infect Dis. 2014;14:349. 10.1186/1471-2334-14-349
   PubMed Web of Science ®Google Scholar
• Avci ME, Arslan F, Ciftci S, et al. Role of spiramycin in prevention of fetal toxoplasmosis. J Matern Fetal Neonatal Med. 2016;29(13):2073–2076. 10.3109/14767058.2015.1074998
   PubMed Web of Science ®Google Scholar
• Peyron F, Wallon M, Liou C, et al. Treatments for toxoplasmosis in pregnancy. Cochrane Database Syst Rev. 2000(2):CD001684.
   Google Scholar
• Couvreur J, Desmonts G, Thulliez P. Prophylaxis of congenital toxoplasmosis. effects of spiramycin on placental infection. J Antimicrob Chemother. 1988;22 Suppl B:193–200. 10.1093/jac/22.Supplement_B.193
   PubMed Web of Science ®Google Scholar
• Valentini P, Annunziata ML, Angelone DF, et al. Role of spiramycin/cotrimoxazole association in the mother-to-child transmission of toxoplasmosis infection in pregnancy. Eur J Clin Microbiol Infect Dis. 2009;28(3):297–300. 10.1007/s10096-008-0612-5
   PubMed Web of Science ®Google Scholar
• Valentini P, Buonsenso D, Barone G, et al. Spiramycin/cotrimoxazole versus pyrimethamine/sulfonamide and spiramycin alone for the treatment of toxoplasmosis in pregnancy. J Perinatol. 2015;35(2):90–94. 10.1038/jp.2014.161
   PubMed Web of Science ®Google Scholar
• Lopes CD, Silva NM, Ferro EA, et al. Azithromycin reduces ocular infection during congenital transmission of toxoplasmosis in the calomys callosus model. J Parasitol. 2009;95(4):1005–1010. 10.1645/GE-1765.1
   PubMed Web of Science ®Google Scholar
• Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58(RR-4):1–207; quiz CE1-4.
   Google Scholar
• Porter SB, Sande MA. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med. 1992;327(23):1643–1648. 10.1056/NEJM199212033272306
   PubMed Web of Science ®Google Scholar
• Carr A, Tindall B, Brew BJ, et al. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med. 1992;117(2):106–111. 10.7326/0003-4819-117-2-106
   PubMed Web of Science ®Google Scholar
• Schneider MM, Hoepelman AI, Schattenkerk JK, et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. N Engl J Med. 1992;327(26):1836–1841. 10.1056/NEJM199212243272603
   PubMed Web of Science ®Google Scholar
• Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. N Engl J Med. 1992;327(26):1842–1848. 10.1056/NEJM199212243272604
   PubMed Web of Science ®Google Scholar
• Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med. 1995;332(11):693–699. 10.1056/NEJM199503163321101
   PubMed Web of Science ®Google Scholar
• Ribera E, Fernandez-Sola A, Juste C, et al. Comparison of high and low doses of trimethoprim-sulfamethoxazole for primary prevention of toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clin Infect Dis. 1999;29(6):1461–1466. 10.1086/313515
   PubMed Web of Science ®Google Scholar
• Girard PM, Landman R, Gaudebout C, et al. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group. N Engl J Med. 1993;328(21):1514–1520. 10.1056/NEJM199305273282102
   PubMed Web of Science ®Google Scholar
• Antinori A, Murri R, Ammassari A, et al. Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. AIDS. 1995;9(12):1343–1350. 10.1097/00002030-199512000-00007
   PubMed Web of Science ®Google Scholar
• Opravil M, Hirschel B, Lazzarin A, et al. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clin Infect Dis. 1995;20(3):531–541. 10.1093/clinids/20.3.531
   PubMed Web of Science ®Google Scholar
• Bucher HC, Griffith L, Guyatt GH, et al. Meta-analysis of prophylactic treatments against pneumocystis carinii pneumonia and toxoplasma encephalitis in hiv-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15(2):104–114. 10.1097/00042560-199706010-00002
   PubMedGoogle Scholar
• Klinker H, Langmann P, Richter E. Pyrimethamine alone as prophylaxis for cerebral toxoplasmosis in patients with advanced HIV infection. Infection. 1996;24(4):324–327. 10.1007/BF01743370
   PubMed Web of Science ®Google Scholar
• Jacobson MA, Besch CL, Child C, et al. Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced human immunodeficiency virus disease: results of a randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS. J Infect Dis. 1994;169(2):384–394. 10.1093/infdis/169.2.384
   PubMed Web of Science ®Google Scholar
• Leport C, Chene G, Morlat P, et al. Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial Group. J Infect Dis. 1996;173(1):91–97. 10.1093/infdis/173.1.91
   PubMed Web of Science ®Google Scholar
• Schurmann D, Bergmann F, Albrecht H, et al. Twice-weekly pyrimethamine–sulfadoxine effectively prevents Pneumocystis carinii pneumonia relapse and toxoplasmic encephalitis in patients with AIDS. J Infect. 2001;42(1):8–15. 10.1053/jinf.2000.0772
   PubMed Web of Science ®Google Scholar
• Durant J, Hazime F, Carles M, et al. Prevention of Pneumocystis carinii pneumonia and of cerebral toxoplasmosis by roxithromycin in HIV-infected patients. Infection. 1995;23(S1):S33–S38. 10.1007/BF02464958
   PubMed Web of Science ®Google Scholar
• Connolly MP, Goodwin E, Schey C, et al. Toxoplasmic encephalitis relapse rates with pyrimethamine-based therapy: systematic review and meta-analysis. Pathog Glob Health. 2017;111(1):31–44. 10.1080/20477724.2016.1273597
   PubMed Web of Science ®Google Scholar
• Montoya JG, Giraldo LF, Efron B, et al. Infectious complications among 620 consecutive heart transplant patients at stanford university medical center. Clin Infect Dis. 2001;33(5):629–640. 10.1086/cid.2001.33.issue-5
   PubMed Web of Science ®Google Scholar
• Baden LR, Katz JT, Franck L, et al. Successful toxoplasmosis prophylaxis after orthotopic cardiac transplantation with trimethoprim-sulfamethoxazole. Transplantation. 2003;75(3):339–343. 10.1097/01.TP.0000044864.99398.F1
   PubMed Web of Science ®Google Scholar
• Baran DA, Alwarshetty MM, Alvi S, et al. Is toxoplasmosis prophylaxis necessary in cardiac transplantation? long-term follow-up at two transplant centers. J Heart Lung Transplant. 2006;25(11):1380–1382. 10.1016/j.healun.2006.08.001
   PubMed Web of Science ®Google Scholar
• Wreghitt TG, Hakim M, Gray JJ, et al. Toxoplasmosis in heart and heart and lung transplant recipients. J Clin Pathol. 1989;42(2):194–199. 10.1136/jcp.42.2.194
   PubMed Web of Science ®Google Scholar
• Strabelli TM, Siciliano RF, Vidal Campos S, et al. Toxoplasma gondii myocarditis after adult heart transplantation: successful prophylaxis with pyrimethamine. J Trop Med. 2012;2012:853562.
   PubMedGoogle Scholar
• Payá E, Noemí I, Tassara R, et al. Prophylaxis against Toxoplasma gondii disease in pediatric and adult patients undergoing solid organ and hematopoietic stem cells transplantation. Rev Chilena Infectol. 2012;29(Suppl 1):37–39. 10.4067/S0716-10182012000500007
   Google Scholar
• Foot AB, Garin YJ, Ribaud P, et al. Prophylaxis of toxoplasmosis infection with pyrimethamine/sulfadoxine (Fansidar) in bone marrow transplant recipients. Bone Marrow Transplant. 1994;14(2):241–245.
   PubMed Web of Science ®Google Scholar
• Mendorf A, Klyuchnikov E, Langebrake C, et al. Atovaquone for prophylaxis of toxoplasmosis after allogeneic hematopoietic stem cell transplantation. Acta Haematol. 2015;134(3):146–154. 10.1159/000380757
   PubMed Web of Science ®Google Scholar
• Conrad A, Le Maréchal M, Dupont D, et al. A matched case-control study of toxoplasmosis after allogeneic haematopoietic stem cell transplantation: still a devastating complication. Clin Microbiol Infect. 2016;22(7):636–641. 10.1016/j.cmi.2016.04.025
   PubMed Web of Science ®Google Scholar